DC-based immunotherapy to treat Malignant Mesothelioma

Publicaciones

A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial

Autores: Robert A. Belderbos, Paul Baas, Rossana Berardi, Robin Cornelissen, Dean A. Fennell, Jan P. van Meerbeeck, Arnaud Scherpereel, Heleen Vroman, Joachim G. J. V. Aerts
Publicado en: Translational Lung Cancer Research, Edición 8/3, 2019, Página(s) 280-285, ISSN 2218-6751
Editor: AME publishing company
DOI: 10.21037/tlcr.2019.05.05

Derechos de propiedad intelectual

METHOD FOR PREPARING AN IMMUNOGENIC LYSATE, THE LYSATE OBTAINED, DENDRITIC CELLS LOADED WITH SUCH LYSATE AND A PHARMACEUTICAL COMPOSITION COMPRISING THE LYSATE OR THE DENDRITIC CELLS

Número de solicitud/publicación: EP 13821476
Fecha: 2013-12-20
Solicitante(s): AMPHERA BV

METHOD FOR PREPARING AN IMMUNOGENIC LYSATE, THE LYSATE OBTAINED, DENDRITIC CELLS LOADED WITH SUCH LYSATE AND A PHARMACEUTICAL COMPOSITION COMPRISING THE LYSATE OR THE DENDRITIC CELLS

Número de solicitud/publicación: EP 13821476
Fecha: 2013-12-20
Solicitante(s): AMPHERA BV

Pharmaceutical composition for use in the treatment of cancer

Número de solicitud/publicación: PCT/NL2017/ 050809
Fecha: 2016-12-02
Solicitante(s): AMPHERA BV